Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2015; 21(25): 7764-7776
Published online Jul 7, 2015. doi: 10.3748/wjg.v21.i25.7764
Published online Jul 7, 2015. doi: 10.3748/wjg.v21.i25.7764
Overexpression of HMGB1 A-box reduced lipopolysaccharide-induced intestinal inflammation via HMGB1/TLR4 signaling in vitro
Fu-Cai Wang, Jing-Xuan Pei, Dong-Sheng Liu, Hui-Fang Xiong, Xiao-Qun Liu, Yong Xie, Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Gastroenterology Institute of Jiangxi Province, Key Laboratory of Digestive Diseases of Jiangxi Province, Nanchang 330006, Jiangxi Province, China
Fu-Cai Wang, Dong-Jia Lin, Department of Immunology, Medical College of Nanchang University, Nanchang 330006, Jiangxi Province, China
Jun Zhu, Department of Pathophysiology, Medical College of Nanchang University, 461 Bayi Road, Nanchang 330006, Jiangxi Province, China
Nan-Jin Zhou, Institute of Immunology and Biological Therapy, Jiangxi Academy of Medical Sciences, Nanchang 330006, Jiangxi Province, China
Author contributions: Wang FC, Pei JX and Zhu J contributed equally to this work; Zhou NJ and Xie Y designed and coordinated the research; Wang FC and Pei JX performed the majority of the experiments; Wang FC, Pei JX and Xie Y analyzed the data; Liu DS and Xiong HF contributed reagents/materials/analysis tools; Wang FC, Pei JX, Zhu J, Liu XQ, Lin DJ and Xie Y wrote the paper.
Supported by National Natural Science Foundation of China, No. 81160056; and the Youth Science Foundation of Jiangxi Provincial, China, No. 20132BAB215017.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest related to the publication of this paper.
Data sharing statement: No additional unpublished data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yong Xie, PhD, Professor, Chief Physician, Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Gastroenterology Institute of Jiangxi Province, Key Laboratory of Digestive Diseases of Jiangxi Province, No. 17 Yongwaizheng Street, Nanchang 330006, Jiangxi Province, China. xieyong_med@163.com
Telephone: +86-791-88692507 Fax: +86-791-88692507
Received: December 5, 2014
Peer-review started: December 6, 2014
First decision: December 22, 2014
Revised: January 12, 2015
Accepted: March 19, 2015
Article in press: March 19, 2015
Published online: July 7, 2015
Peer-review started: December 6, 2014
First decision: December 22, 2014
Revised: January 12, 2015
Accepted: March 19, 2015
Article in press: March 19, 2015
Published online: July 7, 2015
Core Tip
Core tip: We have provided the first report that high mobility group box (HMGB)1 A-box, not only ethyl pyruvate, can specifically inhibit HMGB1/toll-like receptor 4 signaling pathways and reduce lipopolysaccharide-induced intestinal inflammation. Our findings indicate the potential of the HMGB1 A-box as a novel approach in the treatment of inflammatory bowel disease.